Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Mol Cancer Ther
    May 2026
  1. GHAFOOR A, Zhu L, Weaver Ohler Z, El Meskini R, et al
    HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.
    Mol Cancer Ther. 2026 May 1. doi: 10.1158/1535-7163.MCT-25-1077.
    >> Share

    April 2026
  2. LIN YT, Liu YN, Hsu YC, Hsu YC, et al
    Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
    Mol Cancer Ther. 2026 Apr 20:OF1-OF10. doi: 10.1158/1535-7163.MCT-25-1214.
    >> Share

    March 2026
  3. DUTTA CHOWDHURY D, Imada EL, Connis N, Chang J, et al
    TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer.
    Mol Cancer Ther. 2026 Mar 16. doi: 10.1158/1535-7163.MCT-25-0529.
    >> Share

    February 2026
  4. GUO H, Yue C, Ma D, Zhou J, et al
    VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models.
    Mol Cancer Ther. 2026 Feb 12. doi: 10.1158/1535-7163.MCT-25-0965.
    >> Share

    January 2026
  5. SHIELDS MD, Minton KG, Ozakinci H, Zhou T, et al
    ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.
    Mol Cancer Ther. 2026 Jan 26. doi: 10.1158/1535-7163.MCT-25-0663.
    >> Share

    November 2025
  6. SUMII M, Masuda T, Shimoji K, Yamaguchi K, et al
    Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Nov 6. doi: 10.1158/1535-7163.MCT-24-0890.
    >> Share

    September 2025
  7. DENG S, Hussain T, Bartelli TF, Sebastian MM, et al
    Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.
    Mol Cancer Ther. 2025 Sep 30. doi: 10.1158/1535-7163.MCT-25-0392.
    >> Share

  8. PATEL UA, Shi MY, Kazan JM, Nixon KCJ, et al
    CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Sep 25:OF1-OF13. doi: 10.1158/1535-7163.MCT-24-0861.
    >> Share

  9. PATEL UA, Shi MY, Kazan JM, Nixon KCJ, et al
    CRISPR Screen Identifies HDAC3 as a Novel Radiosensitizing Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2025 Sep 3. doi: 10.1158/1535-7163.MCT-24-0861.
    >> Share

  10. BUSENBENDER T, Pelageev DN, Hauschild J, Kaune M, et al
    6-[(1,4-Naphthoquinone-2-yl)methyl]thio-Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer.
    Mol Cancer Ther. 2025;24:1331-1349.
    >> Share

    May 2025
  11. OKAWA S, Tomida S, Kuribayashi T, Nishimura J, et al
    Colony-stimulating factor-1 receptor inhibitor augments osimertinib-induced anti-tumor immunity via suppression of macrophages in lung cancer harboring EGFR mutation.
    Mol Cancer Ther. 2025 May 29. doi: 10.1158/1535-7163.MCT-25-0002.
    >> Share

    April 2025
  12. DOMINGUEZ-VIGIL IG, Banik K, Baro M, Contessa JN, et al
    PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.
    Mol Cancer Ther. 2025 Apr 29. doi: 10.1158/1535-7163.MCT-24-0978.
    >> Share

  13. YUAN R, McGeehan A, Zhou S, Cheng C, et al
    The anti-FRalpha antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell death.
    Mol Cancer Ther. 2025 Apr 28. doi: 10.1158/1535-7163.MCT-24-0649.
    >> Share

    March 2025
  14. KOGAI H, Tsukamoto S, Koga M, Miyano M, et al
    Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.
    Mol Cancer Ther. 2025;24:392-405.
    >> Share

  15. KIM DK, Synn CB, Lee W, Jo HN, et al
    Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
    Mol Cancer Ther. 2025;24:354-369.
    >> Share

    January 2025
  16. LU S, Pan X, Volckova E, Shinde A, et al
    Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models.
    Mol Cancer Ther. 2025 Jan 21. doi: 10.1158/1535-7163.MCT-24-0213.
    >> Share

    December 2024
  17. CALLES A, Calvo E, Santamaria Nunez G, Costanzo F, et al
    Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.
    Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0050.
    >> Share

  18. MARTIN-VEGA A, Earnest SA, Augustyn A, Wichaidit C, et al
    ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers.
    Mol Cancer Ther. 2024;23:1789-1800.
    >> Share

    November 2024
  19. OH MS, Dumitras C, Salehi-Rad R, Tran LM, et al
    Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.
    Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435.
    >> Share

    October 2024
  20. CINA C, Majeti B, O'Brien Z, Wang L, et al
    A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2024 Oct 17. doi: 10.1158/1535-7163.MCT-23-0915.
    >> Share

  21. GUO Q, Gao B, Song R, Li W, et al
    FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Mol Cancer Ther. 2024;23:1367-1377.
    >> Share

    September 2024
  22. GERA N, Fitzgerald KM, Ramesh V, Patel P, et al
    MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells.
    Mol Cancer Ther. 2024;23:1282-1293.
    >> Share

    August 2024
  23. DAVE F, Vaghela P, Heath B, Dunster Z, et al
    SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models.
    Mol Cancer Ther. 2024 Aug 26. doi: 10.1158/1535-7163.MCT-24-0187.
    >> Share

  24. RODRIGUEZ BL, Huang J, Gibson L, Fradette JJ, et al
    Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors.
    Mol Cancer Ther. 2024;23:1144-1158.
    >> Share

  25. NGUYEN T, Carrieri FA, Connis N, Lafargue A, et al
    TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.
    Mol Cancer Ther. 2024;23:1201-1211.
    >> Share

    May 2024
  26. XU Y, Ding K, Peng Z, Ding L, et al
    Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.
    Mol Cancer Ther. 2024;23:733-742.
    >> Share

  27. MA W, Wei S, Li Q, Zeng J, et al
    Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
    Mol Cancer Ther. 2024;23:700-710.
    >> Share

    April 2024
  28. LULLA AR, Akli S, Karakas C, Caruso JA, et al
    Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis.
    Mol Cancer Ther. 2024;23:492-506.
    >> Share

    March 2024
  29. MCCRURY M, Swafford K, Shuttleworth SL, Mehdi SH, et al
    Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.
    Mol Cancer Ther. 2024;23:316-329.
    >> Share

    February 2024
  30. HIRAI S, Yamada T, Katayama Y, Ishida M, et al
    Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
    Mol Cancer Ther. 2024;23:212-222.
    >> Share

    January 2024
  31. CHEN N, Tyler LC, Le AT, Welsh EA, et al
    MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
    Mol Cancer Ther. 2024;23:92-105.
    >> Share

  32. HILLEN H, Candi A, Vanderhoydonck B, Kowalczyk W, et al
    A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Mol Cancer Ther. 2024;23:3-13.
    >> Share

    December 2023
  33. GUAN C, Zhang X, Yu L
    A review of recent advances in the molecular mechanisms underlying brain metastasis in lung cancer.
    Mol Cancer Ther. 2023 Dec 20. doi: 10.1158/1535-7163.MCT-23-0416.
    >> Share

  34. OGIMOTO T, Ozasa H, Tsuji T, Funazo T, et al
    Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
    Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371.
    >> Share

  35. KHAN HY, Nagasaka M, Aboukameel A, Alkhalili O, et al
    Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Mol Cancer Ther. 2023;22:1422-1433.
    >> Share

    September 2023
  36. WENG W, Meng T, Pu J, Ma L, et al
    AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Mol Cancer Ther. 2023;22:1013-1027.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016